- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT02935244
Advanced Understanding of Staphylococcus Aureus Infections in Europe - Surgical Site Infections (ASPIRE-SSI)
Studieöversikt
Status
Betingelser
Detaljerad beskrivning
The primary objective of ASPIRE-SSI is to determine the incidence of S. aureus infections, particularly S. aureus SSIs, in various adult surgical patient populations, and to identify the patient-related, pathogen-related, and contextual risk factors for the development of S. aureus SSI. Using this information, a SSI prediction tool will be derived for future clinical trials and public health interventions aimed at SSI prevention. Furthermore, immunologic features protective against S. aureus SSI will also be assessed.
The knowledge obtained by this study will enable identification of the surgical patients most at risk of developing S. aureus infections, particularly S. aureus SSI, and who would probably benefit most from new interventions given prophylactically and specifically to prevent S. aureus infections.
Studietyp
Inskrivning (Faktisk)
Kontakter och platser
Studieorter
-
-
-
Gent, Belgien
- Algemeen Ziekenhuis Sint-Lucas & Volkskliniek Gent
-
Lier, Belgien
- H. Hartziekenhuis
-
-
-
-
-
Tallin, Estland
- North Estonia Medical Centre
-
Tartu, Estland
- Tartu University Clinic
-
-
-
-
-
Limoges, Frankrike
- Centre Hospitalier Universitaire de Limoges
-
-
-
-
-
Ancona, Italien
- Azienda Ospedaliera Universitaria Ospedali Riuniti, Ancona
-
Brescia, Italien
- Brescia Hospital
-
Rimini, Italien
- Ospedale infermi di Rimini
-
-
-
-
-
Assen, Nederländerna
- Wilhemina Ziekenhuis Assen
-
Breda, Nederländerna
- Amphia Hospital
-
Utrecht, Nederländerna
- UMC Utrecht
-
-
-
-
-
Bukarest, Rumänien
- Carol Davila University of Medicine and Pharmacy Bucharest
-
Bukarest, Rumänien
- Elias University Emergency Hospital
-
Bukarest, Rumänien
- Prof. C.C. Iliescu Cardiovascular Diseases Institute
-
Timişoara, Rumänien
- Clinic County Hospital Timisoara
-
-
-
-
-
Belgrad, Serbien
- Clinical Centre of Serbia
-
Belgrad, Serbien
- Institute for Orthopedic Surgery Banjica
-
Kragujevac, Serbien
- Clinical Centre of Kragujevac
-
-
-
-
-
Barcelona, Spanien
- Hospital Universitari de Bellvitge
-
Cadiz, Spanien
- Hospital Universitari del Mar
-
Córdoba, Spanien
- HU Reina Sophia
-
Oviedo, Spanien
- Hospital Universitario Central de Asturias
-
Sevilla, Spanien
- Hospital Universitario Virgen Macarena
-
-
-
-
-
Birmingham, Storbritannien
- Queen Elizabeth Hospital
-
Brighton, Storbritannien
- Brighton & Sussex University Hospital NHS Trust
-
Derby, Storbritannien
- Derby Teaching Hospitals NHS Foundation Trust
-
Manchester, Storbritannien
- The Pennine Acute Hospitals NHS Trust Manchester
-
Middlesbrough, Storbritannien
- South Tees Hospitals NHS Foundation Trust
-
York, Storbritannien
- York Teaching Hospitals NHS Foundation Trust
-
-
-
-
-
Brno Střed, Tjeckien
- St. Anne's University Hospital Brno
-
Nový Hradec Králové, Tjeckien
- University Hospital Hradec Kralove
-
Ostrava, Tjeckien
- University Hospital Ostrava
-
Praha, Tjeckien
- University Hospital Motol
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Testmetod
Studera befolkning
Patients undergoing 1 of the protocol-defined surgical procedures are eligible for inclusion in the study. However, enrolment in the study cohort population will be based on preoperative S. aureus colonization. In total, approximately 3300 S. aureus colonized subjects and 1700 non-colonized subjects will be enrolled in the study cohort population.
Protocol-defined surgical procedures: Coronary artery bypass grafting; ICD implantation; knee and hip prosthesis surgery; laminectomy and spinal fusion surgery; emergency surgery; central artery reconstructive and peripheral artery bypass surgery; mastectomy; and craniotomy.
Beskrivning
Inclusion Criteria:
- The subject is 18 years of age or older.
- The subject is undergoing 1 of the protocol-defined surgical procedures. The surgical procedure is planned or unplanned.
- The subject has been screened for S. aureus colonization from three body regions: nose, throat, and perineum within 30 days prior to surgery, and based on the preoperative S. aureus colonization status of the subject, the subject qualifies for enrolment in the study cohort.
- Written informed consent has been obtained prior to enrollment in the study cohort.
Exclusion criteria:
- Parallel participation in any experimental study of an anti-Staphylococcus preventive intervention.
- An active diagnosis of a SSI as the reason for surgery.
- Not able to comply with study procedures and follow-up based on Investigator judgment.
Studieplan
Hur är studien utformad?
Designdetaljer
Vad mäter studien?
Primära resultatmått
Resultatmått |
Tidsram |
|---|---|
|
Incidence of S. aureus SSI
Tidsram: Up to 90 days following surgery.
|
Up to 90 days following surgery.
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Incidence of serious S. aureus SSI (deep and organ/space S. aureus SSI)
Tidsram: Up to 90 days following surgery
|
Up to 90 days following surgery
|
|
|
Incidence of S. aureus bloodstream infection
Tidsram: Up to 90 days following surgery
|
Up to 90 days following surgery
|
|
|
Incidence of other post-surgical S. aureus infection
Tidsram: Up to 90 days following surgery
|
Up to 90 days following surgery
|
|
|
Incidence of all-cause SSI, by etiologic agent
Tidsram: Up to 90 days following surgery
|
Up to 90 days following surgery
|
|
|
Incidence of S. aureus SSI stratified by antibiotic susceptibility
Tidsram: Up to 90 days following surgery
|
Up to 90 days following surgery
|
|
|
Prevalence of preoperative S. aureus colonization in nose, throat and perineal region.
Tidsram: No more than 30 days prior to surgery
|
No more than 30 days prior to surgery
|
|
|
Incidence of S. aureus SSI stratified by location of preoperative S. aureus colonization
Tidsram: Up to 90 days following surgery
|
Up to 90 days following surgery
|
|
|
Incidence of post-surgical all-cause mortality
Tidsram: Up to 90 days following surgery
|
Up to 90 days following surgery
|
|
|
Semi-quantification of the bacterial load of colonizing S. aureus
Tidsram: At the time of preoperative screening for S. aureus colonization (within 30 days prior to surgery)
|
At the time of preoperative screening for S. aureus colonization (within 30 days prior to surgery)
|
|
|
Characterization of S. aureus isolates involved in colonization
Tidsram: At the time of preoperative screening for S. aureus colonization (within 30 days prior to surgery)
|
Clonal type, gene sequence, and expression of certain virulence factors of S. aureus isolates
|
At the time of preoperative screening for S. aureus colonization (within 30 days prior to surgery)
|
|
Serum antibody levels against S. aureus virulence factors.
Tidsram: Within 30 days prior to surgery (for the preoperative sample) and 2-6 weeks following the SSI episode (for the post-SSI sample)
|
Within 30 days prior to surgery (for the preoperative sample) and 2-6 weeks following the SSI episode (for the post-SSI sample)
|
|
|
Characterization of S. aureus isolates involved in infections
Tidsram: Up to 90 days following surgery
|
Clonal type, gene sequence, and expression of certain virulence factors of S. aureus isolates
|
Up to 90 days following surgery
|
Andra resultatmått
Resultatmått |
Tidsram |
|---|---|
|
Magnitude of healthcare utilization associated with S. aureus SSI in terms of: a. Duration of length of stay (LOS) b. Incidence of readmissions, including re-interventions due to S. aureus SSI c. Duration of LOS during readmissions
Tidsram: Up to 90 days following surgery
|
Up to 90 days following surgery
|
|
Incidence of S. aureus SSI, stratified by participating country
Tidsram: Up to 90 days following surgery
|
Up to 90 days following surgery
|
|
Incidence of S. aureus SSI, stratified by type of surgery
Tidsram: Up to 90 days following surgery
|
Up to 90 days following surgery
|
|
Incidence of S. aureus SSI, stratified by wound classification
Tidsram: Up to 90 days following surgery
|
Up to 90 days following surgery
|
|
Incidence of S. aureus SSI, stratified by urgency of surgery
Tidsram: Up to 90 days following surgery
|
Up to 90 days following surgery
|
|
Incidence of S. aureus SSI, stratified by American Society of Anesthesiologists Physical Score classification
Tidsram: Up to 90 days following surgery
|
Up to 90 days following surgery
|
Samarbetspartners och utredare
Sponsor
Samarbetspartners
Utredare
- Huvudutredare: Jan AJW Kluytmans, MD PhD, UMC Utrecht
Publikationer och användbara länkar
Användbara länkar
Studieavstämningsdatum
Studera stora datum
Studiestart (Faktisk)
Primärt slutförande (Faktisk)
Avslutad studie (Faktisk)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Uppskatta)
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Nyckelord
Ytterligare relevanta MeSH-villkor
Andra studie-ID-nummer
- NL57595.041.16
Plan för individuella deltagardata (IPD)
Planerar du att dela individuella deltagardata (IPD)?
Läkemedels- och apparatinformation, studiedokument
Studerar en amerikansk FDA-reglerad läkemedelsprodukt
Studerar en amerikansk FDA-reglerad produktprodukt
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .
Kliniska prövningar på Staphylococcus aureus
-
University Hospital TuebingenRekryteringStaphylococcus aureusTyskland
-
Centre Hospitalier Universitaire de Saint EtienneAvslutadStaphylococcus aureusFrankrike
-
University of SheffieldRajarata University, Sri LankaOkänd
-
NovaDigm Therapeutics, Inc.Uniformed Services University of the Health Sciences; Infectious Diseases...AvslutadStaphylococcus aureusFörenta staterna
-
Hospital Universitari de BellvitgeInstitut d'Investigació Biomèdica de Bellvitge; Hospital Universitario... och andra samarbetspartnersAktiv, inte rekryterandeStaphylococcal Aureus-infektion | Staphylococcus Aureus BakteremiSpanien
-
AstraZenecaParexelHar inte rekryterat ännuStaphylococcus Aureus blodomloppsinfektionJapan
-
McGill University Health Centre/Research Institute...University of MelbourneRekryteringStaphylococcus Aureus Bakteremi | Staphylococcus Aureus Endokardit | Staphylococcus Aureus Septikemi | S. Aureus Bakteremi | S. Aureus blodomloppsinfektion | Staphylococcus Aureus blodomloppsinfektionKanada
-
West Virginia UniversityAnmälan via inbjudanStaphylococcus Aureus BakteremiFörenta staterna
-
Intermountain Health Care, Inc.Har inte rekryterat ännuStaphylococcus Aureus BakteremiFörenta staterna
-
Todd C. Lee MD MPH FIDSAUniversity of Melbourne; The Peter Doherty Institute for Infection and...RekryteringStaphylococcus Aureus Bakteremi | Staphylococcus Aureus Endokardit | Staphylococcus Aureus Septikemi | S. Aureus Bakteremi | S. Aureus blodomloppsinfektionAustralien, Kanada